Literature DB >> 25962898

Establishment and characterization of a cell line from human adenoid cystic carcinoma of the lacrimal glands and a nude mouse transplantable model.

Tingting Lin1, Limin Zhu1, Beiqing Zhou1, Lianfeng Xie1, Jianmei Lv1, Lijie Dong1, Yanjin He1.   

Abstract

Using tissue block culture techniques, we established a new human tumor cell line derived from adenoid cystic carcinoma of the lacrimal glands (LACC-1). The LACC-1 cell line was successfully subcultured for more than 100 passages during the last two years. The outgrowth of cells was observed by day 5 after seeding, and then the cells were generated slowly. The first passage proceeded by day 32, and the classical epithelioid cell colonies formed by day 69 after inoculation. After eight passages, homogeneous epithelioid tumor cells appeared when we combined continuous passage, mechanical scraping, repeated adherence, and dissociation methods to remove the fibroblast cells. LACC-1 cells appeared as a histologically solid pattern and continuous passage culture. The population doubling time was approximately 37.1 h. LACC-1 cells appeared as an epithelioid monolayer culture on the cell culture flask and presented with a cobblestone-like appearance when they reached confluency. The nucleus was large and round with many abnormal mitoses. The nucleoplasm ratio was high. Multinucleated tumor giant cells appeared. LACC-1 cells showed a tendency to have overlapping growth without contact inhibition when the cell density continued to increase. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) showed that the LACC-1 cells were malignant tumor cells that were poorly differentiated. The surface of the LACC-1 cells exhibited affluent microvilli, protuberances and filopodia under SEM. The no. 84 generation LACC-1 cell line was inoculated subcutaneously into the subaxillary of nude mice and the tumorigenic potential was evident. The formation rate of the transplanted tumors was 100% at day 7 after inoculation. This finding showed that the LACC-1 cell line was malignant with tumorigenic ability. The xenograft tumors retained the same histological characteristics of a solid pattern as the LACC-1 original tumor after inoculation for 49 days. Under TEM observation, the xenograft tumor cells had the same ultrastructure as the LACC-1 cells. Immunohistochemical examination revealed the similarity of both cytoskeletal proteins (e.g., cytokeratin, vimentin, desmin and α-SMA) and S-100 expression in the original tumor, LACC-1 cells and xenograft tumors. Immunoreactivity of these proteins was gradually decreased in these three tissues. Reverse transcription-polymerase chain reaction demonstrated that the xenograft tumors originated from the human. Based on these results, the LACC-1 cell line provides a useful model for studying the biological characteristics of human ACC of the lacrimal glands.

Entities:  

Mesh:

Year:  2015        PMID: 25962898     DOI: 10.3892/or.2015.3925

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.

Authors:  Yue Jiang; Ruli Gao; Chunxia Cao; Lauren Forbes; Jianping Li; Shelby Freeberg; Kristianna M Fredenburg; Jeb M Justice; Natalie L Silver; Lizi Wu; Sushama Varma; Robert West; Jonathan D Licht; Maria Zajac-Kaye; Alex Kentsis; Frederic J Kaye
Journal:  Oral Oncol       Date:  2019-10-10       Impact factor: 5.337

2.  A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug.

Authors:  Chen Chen; Sujata Choudhury; Darawalee Wangsa; Chamille J Lescott; Devan J Wilkins; Praathibha Sripadhan; Xuefeng Liu; Danny Wangsa; Thomas Ried; Christopher Moskaluk; Michael J Wick; Eric Glasgow; Richard Schlegel; Seema Agarwal
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

3.  miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L.

Authors:  Jie Hao; Xin Jin; Yan Shi; Hong Zhang
Journal:  Cancer Cell Int       Date:  2018-05-09       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.